For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and CEO
(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126 (Public Relations)
+81-3-6225-1125 (Investor Relations)
http://www.daiichisankyo.com/

Announcement of Launch Date in Japan for Inavir(R) Influenza Antiviral Inhalant

Tokyo, Japan (September 29, 2010) – Daiichi Sankyo Company, Limited announced today that it will launch Inavir® Dry Powder Inhaler 20mg (generic name: laninamivir octanoate hydrate; approval for manufacture and marketing in Japan: September 10) on Tuesday, October 19, for treatment of influenza in Japan.